BiotechTube
HeartSciences

HeartSciences

Southlake, United States· Est.
heartsciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $36.5M

Overview

HeartSciences is developing a suite of AI-enhanced electrocardiography (AI-ECG) diagnostic solutions to address the critical gap in early heart disease detection. The company offers both a cloud-based platform (MyoVista Insights) that works with existing ECG devices and a proprietary hardware device (MyoVista wav ECG) that incorporates its AI algorithms. By leveraging AI to uncover subtle cardiac dysfunction from ECG signals, HeartSciences targets the massive global cardiovascular diagnostics market, seeking to enable earlier intervention and improve patient outcomes. The company is building a broad portfolio of AI-ECG algorithms backed by clinical publications.

Cardiovascular

Technology Platform

Artificial Intelligence-Enhanced Electrocardiography (AI-ECG) platform that applies machine learning algorithms to standard ECG signals to detect subtle patterns indicative of heart disease. Includes proprietary signal processing technology for enhanced waveform analysis.

Funding History

3
Total raised:$36.5M
IPO$20M
Series B$10M
Series A$6.5M

Opportunities

The massive, global prevalence of cardiovascular disease and the limitations of the conventional ECG create a significant need for better early detection tools.
HeartSciences' AI-ECG platform can be deployed via the existing installed base of millions of ECG devices through its cloud solution, enabling rapid, scalable market penetration.
The technology addresses a critical gap in primary care and screening settings, potentially enabling earlier referrals and treatment.

Risk Factors

Clinical adoption and reimbursement are major hurdles, requiring robust, prospective trials to prove clinical utility and cost-effectiveness.
The company faces competition from both large medical device incumbents integrating AI and well-funded tech companies entering the digital health space.
Regulatory pathways for AI-based software as a medical device (SaMD) are complex and evolving.

Competitive Landscape

HeartSciences competes in the emerging AI-ECG diagnostics space. Competition includes large medtech companies (e.g., GE Healthcare, Philips) developing their own AI capabilities, other specialized AI cardiology startups (e.g., AliveCor, Eko Health), and technology giants (e.g., Apple, Google) exploring health applications. Differentiation relies on algorithm performance, clinical validation, regulatory clearance, and ease of integration into clinical workflow.

More companies in AI / Machine Learning →More companies in United States →